ARGX Stock Overview
A biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €468.10 |
| 52 Week High | €493.60 |
| 52 Week Low | €271.00 |
| Beta | 0.31 |
| 11 Month Change | 2.81% |
| 3 Month Change | 34.74% |
| 1 Year Change | -2.11% |
| 33 Year Change | 58.68% |
| 5 Year Change | 294.69% |
| Change since IPO | 5,825.32% |
Recent News & Updates
Is argenx SE (EBR:ARGX) Trading At A 45% Discount?
Aug 24
Results: argenx SE Confounded Analyst Expectations With A Surprise Profit
Jul 29Recent updates
Is argenx SE (EBR:ARGX) Trading At A 45% Discount?
Aug 24Results: argenx SE Confounded Analyst Expectations With A Surprise Profit
Jul 29argenx SE's (EBR:ARGX) Shares Climb 26% But Its Business Is Yet to Catch Up
Jun 26argenx SE's (EBR:ARGX) CEO Looks Like They Deserve Their Pay Packet
May 01Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects
Apr 11Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report
Mar 24Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report
Mar 05argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate
Feb 23Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely
Dec 18Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher
Jul 28An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued
Jul 17Revenues Tell The Story For argenx SE (EBR:ARGX)
Jun 20argenx (EBR:ARGX) Is Using Debt Safely
May 08We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth
Apr 20Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?
Dec 27Shareholder Returns
| ARGX | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | 0.8% | 1.8% | 0.7% |
| 1Y | -2.1% | -1.8% | 6.0% |
Return vs Industry: ARGX matched the Belgian Biotechs industry which returned -1.8% over the past year.
Return vs Market: ARGX underperformed the Belgian Market which returned 6% over the past year.
Price Volatility
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in BE Market | 7.3% |
| 10% least volatile stocks in BE Market | 2.4% |
Stable Share Price: ARGX's share price has been volatile over the past 3 months.
Volatility Over Time: ARGX's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,148 | Tim Van Hauwermeiren | www.argenx.com |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
argenx SE Fundamentals Summary
| ARGX fundamental statistics | |
|---|---|
| Market cap | €27.99b |
| Earnings (TTM) | -€184.89m |
| Revenue (TTM) | €1.50b |
18.6x
P/S Ratio-151.4x
P/E RatioIs ARGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARGX income statement (TTM) | |
|---|---|
| Revenue | US$1.66b |
| Cost of Revenue | US$1.12b |
| Gross Profit | US$540.20m |
| Other Expenses | US$744.55m |
| Earnings | -US$204.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -3.42 |
| Gross Margin | 32.55% |
| Net Profit Margin | -12.31% |
| Debt/Equity Ratio | 0% |
How did ARGX perform over the long term?
See historical performance and comparison